<DOC>
	<DOCNO>NCT00005820</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness nitrocamptothecin treat men stage IV prostate cancer respond hormone therapy .</brief_summary>
	<brief_title>Nitrocamptothecin Treating Patients With Stage IV Prostate Cancer That Has Not Responded Hormone Therapy</brief_title>
	<detailed_description>OBJECTIVES : - Determine therapeutic efficacy nitrocamptothecin patient metastatic , hormone refractory prostate cancer . - Determine time disease progression duration response patient population result treatment regimen . - Determine safety , tolerance , toxicity treatment regimen patient . OUTLINE : Patients receive nitrocamptothecin orally daily 5 consecutive day week 3 consecutive week . Treatment continue every 4 week absence disease progression unacceptable toxicity . Patients follow every 3 month evidence progression relapse maximum 2 year date registration . PROJECTED ACCRUAL : A total 22-46 patient accrue study 2 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate clinically progressive stage IVA IVB disease least primary androgen ablation either orchiectomy LHRH agonist one cytotoxic chemotherapy regimen Measurable disease maximum 10 measurable lesion OR nonmeasurable disease Serum testosterone great 50 ng/mL prior bilateral orchiectomy PATIENT CHARACTERISTICS : Age : Not specify Performance status : ECOG 0 1 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 ( transfusion independent ) No disseminated intravascular coagulation Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) AST ALT great 3 time ULN Renal : Creatinine great 1.5 time ULN Other : Fertile patient must use effective contraception No currently active second malignancy nonmelanoma skin cancers No active infection PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy recover Chemotherapy : See Disease Characteristics At least 6 week since prior suramin At least 4 week since prior chemotherapy No prior therapy camptothecin analogue Endocrine therapy : Prior second line hormonal therapy allow At least 4 week since prior hormonal therapy Concurrent treatment LHRH agonists allow required patient without orchiectomy No concurrent hormonal therapy except nondisease related condition Concurrent corticosteroid allow stable dose least 6 week study No concurrent dexamethasone antiemetic Radiotherapy : At least 4 week since prior radiotherapy recover No palliative radiotherapy At least 8 week since prior strontium 89 samarium 153 Surgery : At least 3 week since major surgery recover</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>